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This study was aimed to explore whether an antihypertensive lactoferrin 
hydrolysate (LFH) can inhibit angiotensin I-converting enzyme (ACE) activity and 
modify the expression of genes related to hypertension in human umbilical vein 
endothelial cells (HUVEC). LFH induced significant inhibition of ACE activity but 
it did not affect ACE mRNA levels after 24 h of exposure. LFH treatment 
significantly affected the expression of genes encoding for proteins involved in 
nitric oxide pathway such as soluble guanylate cyclase 1 3 subunit (GUCY1A3; 
4.42-fold increase) and nitric oxide synthase trafficking (NOSTRIN; 2.45-fold 
decrease). Furthermore, expression of the PTGS2/COX-2 gene encoding 
prostaglandin-endoperoxide synthase 2 a key component of prostaglandin 
synthesis was significantly increased (2.23-fold). Moreover, NOSTRIN mRNA 
downregulation was consistent with reduced NOSTRIN protein expression and 
increased NO production observed in HUVEC. The present study reveals the 
complexity of the effects exerted by LFH opening avenues for the better 
understanding of its antihypertensive effects. 
Keywords: lactoferrin hydrolysate, ACE inhibition, endothelial cells, 
transcriptomic analysis, NOSTRIN, nitric oxide. 
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Abbreviations 
ACE, angiotensin I-converting enzyme; ACTB, -actin; ARG2, arginase type II; 
AT1, angiotensin type 1 receptor; B2, kinin type 2 receptor; BCA, bicinchoninic 
acid method; ECE, endothelin converting enzyme; eNOS, endothelial nitric oxide 
synthase; Fmoc, N-(9-fluorenyl) methoxycarbonyl; GUCY1A3, guanylate cyclase 
1, soluble, alpha 3; HUVEC, human umbilical vein endothelial cells; LF, bovine 
lactoferrin; LFH, lactoferrin pepsin hydrolysate; NO, nitric oxide; NOSTRIN; nitric 
oxide synthase trafficking; PBS, phosphate buffered saline solution; PTGS2, 
prostaglandin-endoperoxide synthase 2; qRT-PCR, quantitative reverse 
transcription-polymerase chain reaction; RASS, renin-angiotensin-aldosterone 
system; RPL13A, ribosomal protein L13a; SBP, systolic blood pressure; SHRs, 
spontaneously hypertensive rats. 
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1. Introduction 
Hypertension is one of the most prevalent risk factors associated with 
cardiovascular diseases, the leading cause of death in Western countries. During 
the last two decades many studies have focused on the dietary prevention of 
hypertension development, with particular interest in food-derived bioactive 
peptides with inhibitory effects on angiotensin I converting enzyme (ACE). Some 
of these food-derived peptides can control arterial blood pressure in hypertensive 
animals after a single oral dose and also during chronic administration. Moreover, 
some of them may reduce systolic and diastolic blood pressure in hypertensive 
patients (Martínez-Maqueda, Miralles, Recio, & Hernández-Ledesma, 2012). 
ACE, as part of the renin-angiotensin-aldosterone system (RAAS), 
hydrolyzes both the inactive angiotensin I into vasoconstrictor angiotensin II and 
the vasodilator bradykinin into inactive peptide fragments leading to increased 
blood pressure (Carey & Siragy, 2003). Most well-known effects of angiotensin 
II, including vasoconstriction and release of vasopressin and aldosterone, are 
mediated by angiotensin type 1 receptors (AT1) (Brewster & Perazella, 2004) 
whereas bradykinin acts mainly via kinin type 2 receptors (B2) which lead to the 
production of nitric oxide (NO), a vasorelaxing factor (Hillmeister & Persson, 
2012). 
Despite numerous efforts, the in vivo mechanism underlying vasoactive 
and blood pressure lowering effects of antihypertensive food-derived peptides 
has not yet been fully established. Beyond in vivo ACE inhibition reported for 
some peptides and hydrolysates (Yang, Yang, Chen, Tzeng, & Han, 2004; Lu et 
al., 2011; Wang et al., 2012; García-Tejedor et al., 2014), antihypertensive effects 
can be mediated via other components of the RAAS system, such as renin which 
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catalyzes the cleavage of the N-terminal region of angiotensinogen to release 
angiotensin I (Udenigwe, Lin, Hou, & Aluko, 2009; Fitzgerald et al., 2012; Ajibola, 
Fashakin, Fagbemi, & Aluko, 2013). Moreover, emerging evidence points to the 
argininenitric oxide pathway, the endothelin system or opioid receptors as 
molecular targets for food-derived antihypertensive peptides (Udenigwe & 
Mohan, 2014). 
In previous studies, antihypertensive properties of peptides derived from 
bovine lactoferrin (LF), a well-characterized component of milk whey, were 
extensively characterized (Centeno et al., 2006; Ruiz-Giménez et al., 2010). 
Focusing on the RAAS system, we have shown vasoactive effects of a LF pepsin 
hydrolysate (LFH) through ACE inhibition (Ruiz-Giménez et al., 2007) and its 
orally antihypertensive effect in spontaneously hypertensive rats (SHR) after 
acute administration (Ruiz-Giménez et al., 2012). Moreover, chronic 
administration of LFH resulted in reductions of circulating ACE activity, 
angiotensin II and aldosterone levels, as well as a compensatory increase of renin 
activity (Fernández-Musoles, Manzanares, Burguete, Alborch, & Salom, 2013a). 
Recently we have suggested that inhibition of angiotensin II-induced 
vasoconstriction by blocking angiotensin AT1 receptors is a potential mechanism 
also contributing along with ACE inhibition to the antihypertensive effect of LFH 
(Fernández-Musoles et al., 2014). Beyond its effect on the RAAS system, LFH 
might act as dual vasopeptidase inhibitor since it also inhibits endothelin-
converting enzyme (ECE), a key enzyme of the endothelin system involved in 
vascular tone and blood pressure regulation (Fernández-Musoles et al., 2010; 
Fernández-Musoles et al., 2013b). 
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Endothelial cells line the internal surface of blood vessels, play critical roles 
in vascular biology and represent a good model to evaluate the molecular 
mechanisms involved in blood pressure regulation. Since the effects of 
antihypertensive peptides might result from synergic interactions with several 
targets, global approaches represent a feasible strategy for revealing the action 
of these peptides through distinct pathways. With the aim of characterizing the 
effect of LFH at the cellular level, its inhibitory effect on ACE activity in cultured 
human endothelial cells was determined. Moreover, the effects of LFH on the 
expression of a panel of genes related to hypertension were evaluated in these 
cells. Finally, in the light of mRNA expression results, the effects of LFH on the 
NO pathway, including NO production, have been specifically assessed. 
2. Materials and methods 
2.1. Materials 
Bovine LF was provided by FrieslandCampina Domo (Zwolle, The Netherlands). 
Bicinchoninic acid protein assay kit, porcine pepsin, gelatin, monoclonal anti--
Actin antibody and trypan blue were purchased from Sigma-Aldrich (St. Louis, 
MO, USA). ACE substrate o-aminobenzoyl-Gly-p-nitro-Phe-Pro was provided by 
Bachem Feinchemikalien (Bubendorf, Switzerland). Primary human umbilical 
vein endothelial cells (HUVEC) pooled from two to four different umbilical cords 
(Advancell, Barcelona, Spain) were a kind gift of Dr. Isabel Fariñas (Department 
of Cellular Biology, Universidad de Valencia, Spain). EndoGRO-VEGF complete 
medium kit was provided by Millipore (Darmstadt, Germany). Phosphate buffered 
saline solution (PBS) and trypsin-EDTA solution were obtained from HyClone 
(Logan, UT, USA). RNeasy Mini Kit, RT2 First Strand Kit and Human 
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Hypertension RT² Profiler PCR Array from SABiosciences were purchased 
from Qiagen (Valencia, CA, USA). LightCycler® 480 SYBR Green I Master and 
Complete Mini protease-inhibitor cocktail were provided by Roche Diagnostics 
(Basel, Switzerland). Protran BA 85 nitrocellulose, horseradish peroxidase-linked 
species-specific secondary antibodies and ECL Select Western Blotting 
Detection Reagent were purchased from GE Healthcare (Buckinghamshire, 
United Kingdom). Polyclonal anti-mNOSTRIN antibody was a kind gift of Dr. 
Stephanie Oess (Goethe Universität, Frankfurt am Main, Germany). 
2.2. Bovine Lactoferrin Enzymatic Hydrolysate (LFH) and Synthetic Peptides 
Bovine lactoferrin was hydrolyzed using porcine pepsin and the product was 
subjected to ultrafiltration through a polyethersulfone membrane with a 3 kDa cut-
off (Vivascience, Sartorius Stedim Biotech, Aubagne, France) as previously 
described (Ruiz-Giménez et al., 2012). The permeate (LFH) was kept at -20oC 
until use.
Peptides of sequences LIWKL and RPYL were purchased at >95% purity 
from GenScript Corporation (Piscataway, NJ, USA), wherein they were 
synthesized by solid phase methods using N-(9-fluorenyl) methoxycarbonyl 
(Fmoc) chemistry. Stock solutions (10 mM) of each peptide were prepared in 
water, sterilized by filtration and stored at -20oC. 
Protein content of LFH was estimated by the bicinchoninic acid method 
(BCA) using bovine serum albumin as standard (Ruiz-Giménez et al., 2012). 
Synthetic peptide concentration was based on the dry weight of the peptides. 
2.3. Cell Culture 
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HUVEC were maintained in culture using EndoGRO-VEGF complete medium kit 
and seeded onto plasticware previously coated with a sterile solution containing 
1% (w/v) gelatin in distilled water, for at least 90 minutes at 37ºC. Cell integrity 
was checked daily using an inverted phase-contrast microscope, and they were 
subcultured before reaching 90% confluence. 
Cells from passages 3 to 5 were washed with PBS solution, detached with 
trypsin-EDTA solution, resuspended in complete medium and evaluated for 
viability by microscopic observation of cells stained with 0.2 % trypan blue. 
HUVEC were seeded onto gelatin-coated 6-well plates at a cellular density of 
25.000 viable cells/cm2. Twenty four hours after seeding, the corresponding 
treatment was added directly to the cell culture supernatant, and maintained in 
contact with the cells for additional 24 hours. The treatments were used at the 
following final concentrations: LFH 700 µg/mL; RPYL and LIWKL, 100 µM. At the 
end of the experiments cell viability was determined by the trypan blue exclusion 
method. No loss of viability was observed after any of the treatments. 
2.4. ACE Activity Measurements 
Three different biological replicates of either the control (non-treated cells), or 
LFH-treated cells, were evaluated for ACE activity present in cell culture 
supernatants. Activity was measured in all the replicates just before treatment 
(zero time) and at 1, 3, 6 and 24h after addition of LFH. ACE activity was 
measured using the fluorescent method described by Sentandreu & Toldrá 
(2006) with some modifications. Fifty µL samples were taken at every time point 
along the experiment, and transferred to a 96-well black plate. Two hundred µL 
of the internally quenched fluorescent substrate o-aminobenzoyl-Gly-p-nitro-Phe-
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Pro (0.45 mM) were added and the production of the fluorescent product by ACE 
activity was recorded (excitation 320 nm, emission 405 nm) every 30 minutes for 
at least 4 hours using a Fluoroskan Ascent FL (ThemoFisher, Waltham, MA ). 
Relative ACE activity in treated cells was referred to controls at the same time 
points. 
2.5. RNA Isolation and Real-time Quantitative Reverse Transcription-Polymerase 
Chain Reaction (qRT-PCR) Analysis 
After the 24h treatment period, cell culture supernatants were aspired and stored 
at -20oC for nitric oxide measurements. The cells were washed with PBS and 
lysed for obtaining total RNA and total protein extracts using RNeasy Mini Kit. 
Total RNA was DNase-digested on column and was finally eluted in RNase-free 
water. The RNA concentration and purity was measured using a Nanodrop 
ND1000 spectrophotometer (ThermoFisher).
All the PCR reactions were carried out in 96-well plate format in a 
LightCycler 480 instrument (Roche). For the transcriptomic analysis of HUVEC, 
2 µg of total RNA were retro-transcribed using RT2 First Strand Kit, which includes 
an additional step for genomic DNA elimination. The cDNA obtained was used 
as template for the quantitation of the mRNA levels of 84 genes related to 
hypertension, by the use of the Human Hypertension RT² Profiler PCR Array. 
The complete gene list, including housekeeping genes and PCR controls is 
accessible online (www.SABiosciences.com). The qPCR reactions were carried 
out using the RT²SYBR green qPCR mastermix. The CT data were obtained by 
the LighCycler 480 software (release 1.5.0) and were analysed by the CT
method using web-based software specific for the analysis of PCR array data 
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(SABiosciences, Qiagen). Four different biological replicates for each control or 
treatment condition were assayed for mRNAs quantitation. 
Further quantification of mRNA levels was carried out for those genes 
whose expression ratio obtained using the PCR array was modified with statistical 
significance by a factor of 2 or greater. For that purpose, specific oligonucleotide 
pairs used as PCR primers were selected for guanylate cyclase 1, soluble, alpha 
3 (GUCY1A3; forward: 5-GTCCTGCAGTGTACCACGAA-3, reverse: 5-
GGCAGATTCCGGGGATTTCA-3; product length: 140 bp), nitric oxide synthase 
trafficking (NOSTRIN; forward: 5-CTCAACCCAGCCATCCTTGT-3, reverse: 5-
GATTGCTCTGCCCACCAGAA-3; product length: 147 bp), and prostaglandin-
endoperoxide synthase 2 (PTGS2; forward: 5-CGACTCCCTTGGGTGTCAAA-
3, reverse: 5-AAGTGCTGGGCAAAGAATGC-3; product length: 136 bp); and 
also for the housekeeping genes selected, namely -actin (ACTB; forward: 5-
AGCGAGCATCCCCCAAAGTTCAC-3, reverse: 5-
GGGTGGCTTTTAGGATGGCAAGG-3; product length: 127 bp), and ribosomal 
protein L13a (RPL13A; forward: 5-TGCCCCACAAAACCAAGCGAGG-3, 
reverse: 5-AGGCTTCAGACGCACGACCTTG-3; product length: 131 bp). In 
those cases, 3.5 µg of total RNA were retro-transcribed using RT2 First Strand 
Kit in a final volume of 111 µL. Two µL of that dilution was used as template in a 
10 µL PCR reaction using the LightCycler® 480 SYBR green I master. Primers 
were used at a final concentration of 250 nM and efficiency was determined for 
every primer pair at this final concentration using a pooled cDNA as template. 
The CT data were obtained by the LighCycler® 480 software (release 1.5.0) and 
were analyzed by the CT method using the Relative Expression Software Tool 
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version 2.0.13 (Qiagen). Three different biological replicates for each control or 
treatment condition were assayed for specific mRNAs quantitation. 
2.6. Quantitation of NOSTRIN Protein Levels by Western Blot 
Flow-through from the RNA-purification column was precipitated with 4 volumes 
of cold acetone, let stay on ice for 30 min and centrifuged at maximum speed in 
a microcentrifuge for 10 min. The pellet was resuspended in buffer (50 mM Tris, 
10 mM NaCl, 2 mM EDTA, 1% v/v Igepal CA 630, 5% v/v glycerol, 1mM 
phenylmethylsulfonyl fluoride) containing Complete Mini protease-inhibitor 
cocktail. Equivalent amounts of the total protein extracts were separated by SDS-
PAGE and blotted onto Protran BA 85 nitrocellulose. The membranes were 
probed using polyclonal anti-mNOSTRIN antibody which recognizes human 
NOSTRIN with an apparent molecular mass slightly under 60 kDa and also using 
monoclonal anti--Actin antibody (Sigma-Aldrich). Horseradish peroxidase-linked 
species-specific were used as secondary antibodies. The probed membranes 
were developed by chemiluminiscence with ECL Select Western Blotting 
Detection Reagent using a LAS-1000 instrument (Fujifilm, Tokyo, Japan). 
Densitometric analysis of the bands was performed using ImageJ 1.48v software 
(NIH, Bethesda, MD, USA).
2.7. Nitric Oxide Content 
Nitric oxide generation was estimated in cell culture supernatants by quantitation 
of its stable product nitrite using colorimetric determination with the Griess 
reagent (Tsikas, 2007). In brief, cell culture supernatants were deproteinized with 
zinc sulphate (final concentration 1.5% w/v; 5 min on ice), centrifuged at 
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maximum speed for 15 minutes in a microcentrifuge, and equal volumes of the 
clear supernatant and of the Griess reagent incubated at room temperature for 
15 minutes. Absorbance at 540 nm was recorded for blanks and samples. A 
standard curve for nitrite was obtained using concentrations between 0 and 1.25 
µM of sodium nitrite dissolved in complete HUVEC medium. 
2.8. Statistics 
Data are mean ± SEM of n independent assays. Significant differences between 
non-treated and treated HUVEC were evaluated by Students t-test. Differences 
with P-values < 0.05 were considered significant. Data statistical analysis was 
performed using the GraphPad Prism 4 software (GraphPad Software Inc, La 
Jolla, CA, USA). 
3. Results 
3.1. Effect of LFH on ACE activity 
In in vitro tests carried out with purified porcine ACE, LFH showed inhibitory 
potency with an IC50 value of 14.3 ± 3.3 µg/mL (Ruiz-Giménez et al., 2012) while 
in in vivo studies LFH provoked reduction of serum ACE activity after long-term 
administration to SHR (Fernández-Musoles et al., 2013a). Since variations in the 
inhibition profiles of ACE from different species have been reported (Vazeux, 
Cotton, Cuniasse, & Dive, 2001) and with the aim to further characterize LFH 
inhibitory effects on ACE activity at cellular level, here we have investigated such 
effects in cultured HUVEC which produce and secrete ACE. 
Table 1 shows ACE residual activity in HUVEC incubated for 24 h with LFH 
(700 µg/mL) with respect to non-treated cells (control). LFH induced a significant 
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inhibition of ACE activity. After 1 h of treatment, when maximum inhibitory effect 
was observed, ACE residual activity in LFH-treated cells was 15.3 ± 0.4 %.The 
inhibitory effect remained significant up to 24 h (P < 0.05; Students t test) and it 
was higher than 60 %. 
3.2. Effect of LFH on gene expression profile of hypertension-related genes 
RT-qPCR analysis was performed to quantify relative mRNA levels of 
hypertension related-genes in HUVEC exposed to 700 µg/mL LFH. Gene 
expression in HUVEC treated with LFH was compared with expression in non-
treated cells (Table 2). 
Out of the 84 genes included in the array, expression of 51 genes could 
be detected in the conditions tested. LFH treatment caused statistically significant 
upregulation of 4 genes (ARG2, GUCY1A3, GUCY1B3 and PTGS2) and 
downregulation of 2 genes (ATP6AP2 and NOSTRIN). Genes whose expression 
was modified by a factor of 2 or greater, were GUCY1A3 (4.42-fold) and PTGS2 
(2.23-fold) that were upregulated, and NOSTRIN (2.45-fold) that was 
downregulated. GUCY1A3 which encodes guanylate cyclase 1 3 subunit and 
NOSTRIN which encodes NO synthase trafficking are related to NO generation, 
whereas PTGS2 (also called COX2) which encodes prostaglandin-endoperoxide 
synthase 2 or cyclooxygenase 2 is a key component of the prostaglandin 
synthesis. Based on their expression profiles, these three genes were considered 
for further studies. 
3.3. Effect of LFH and lactoferrin-derived peptides on GUCY1A3, PTGS2 and
NOSTRIN expression
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LFH is a complex lactoferrin hydrolysate enriched in peptides of molecular weight 
lower than 3 kDa. In previous studies, we further characterized LFH by 
chromatographic fractionation and 38 peptides contained in the ACE-inhibitory 
fractions were identified. Three of the most abundant peptides corresponded to 
sequences LIWKL, RPYL and LNNSRAP, which showed inhibitory effects on 
ACE and acute antihypertensive effects in SHRs (Ruiz-Giménez et al., 2012). To 
determine if the two most potent antihypertensive peptides, corresponding to 
sequences LIWKL and RPYL, could at least in part contribute to the effect of LFH 
on gene expression in HUVEC, the effect of both sequences on GUCY1A3, 
PTGS2 and NOSTRIN relative mRNA levels was studied in independent RT-
qPCR experiments using primers different to those included in the array. For 
proper comparison, the effect of LFH was re-evaluated using the same self-
designed primer pairs. 
 The effects of LFH and peptide treatments on relative mRNA levels are 
shown in Figure 1. Effects of LFH treatment on the expression of the three 
selected genes were similar to those detected by the array (Table 2), thus 
confirming array expression results. Regarding sequences LIWKL and RPYL, 
treatments (100 µM) did not change mRNA expression of any of the three genes 
evaluated suggesting that, in the conditions tested, these two sequences might 
not be responsible of the effects on mRNA levels observed after LFH treatment 
of HUVEC. 
3.4. Effect of LFH on NOSTRIN protein levels and on NO production 
NOSTRIN is a regulatory protein which modulates NO production (Zimmermann 
et al., 2002), and NO-mediated vasodilation has been attributed to some food-
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derived peptides (Boelsma & Kloek, 2009; García-Redondo, Roque, Miguel, 
López-Fandiño, & Salaices, 2010). This prompted us to further study NOSTRIN 
as a target for LFH and to investigate whether the reduction of NOSTRIN mRNA 
levels detected after LFH treatment resulted in any change in protein expression 
and in NO production. 
NOSTRIN protein levels were detected by immunoblot analysis, as can be 
seen in Figure 2. Twenty-four h-treatment with LFH reduced NOSTRIN protein 
level by 60 % in HUVEC (P < 0.05; Students t test). To determine the time-
dependent generation of NO, measured as nitrite, HUVEC were cultured in the 
presence of 700 µg/mL LFH up to 24 h. Figure 3 shows enhanced nitrite 
production in LFH-treated HUVEC. Although this trend was observed along the 
time course experiment, it reached statistical significance at 24h (P < 0.05; 
Students t test). At this time point, nitrite accumulated in LFH-treated HUVEC 
supernatants was 45% higher than that of control. 
4. Discussion 
The mechanisms underlying the antihypertensive effects of food-protein derived 
enzymatic hydrolysates and peptides have not been yet fully established and 
based on recent knowledge it seems clear that multiple mechanisms besides 
ACE inhibition might be involved (Udenigwe & Mohan, 2014; Marques et al., 
2012). In this study, we examined whether human ACE is inhibited by a complex 
LFH and we explored potential additional targets contributing to its 
antihypertensive effect by analyzing hypertension-related gene expression using 
cultured human endothelial cells. 
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 Inhibition of ACE activity by LFH at a concentration of 700 µg/mL was 
shown in cultured HUVEC supernatants. LFH-inhibitory action on ACE was 
comparable to that reported for two casein trypsin hydrolyates which showed IC50
values in the µg/mL level (Rousseau-Ralliard et al., 2010). Despite inhibition of 
ACE activity at 24 h, LFH did not affect ACE mRNA levels at the same time point. 
Although transcriptional regulation of ACE at earlier time points cannot be 
discarded, our results are in agreement with previous works that describe no 
significant changes in expression of genes associated with RAAS in aorta of SHR 
after repeated administration of the well-known ACE-inhibitory peptides VPP and 
IPP were described (Yamaguchi, Kawaguchi, & Yamamoto, 2009). In HUVEC, 
VPP and IPP had no effect on ACE protein expression, although ACE mRNA 
levels were not evaluated (Hirota et al., 2011). By contrast, downregulation of the 
mRNA levels of renin, ACE and AT1 was reported in kidney from SHRs after 
repeated treatment with the ACE-inhibitory sequences IQP and RVPSL (Lu et al., 
2011; Yu, Yin, Zhao, Chen, & Liu, 2014). Despite ECE has also been described 
as a target for LFH (Fernández-Musoles et al., 2013b), and similarly to what we 
describe here for ACE gene expression, we did not find significant changes in 
ECE relative mRNA level or in expression of other genes associated with the 
endothelin system (EDN1, EDN2, EDNRA, EDNRB, see Table 2). Time-course 
effect of LFH in HUVEC on mRNA levels of genes associated with RAAS and 
endothelin system are necessary to discard any regulation at the mRNA level at 
shorter exposure times. Regulation via post-transcriptional or post-translational 
mechanisms such as mRNA stability and translation and protein-protein 
interactions cannot be ruled out (Chattopadhyay et al., 2005; Kohlstedt et al., 
2013). 
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In this study, expression of the PTGS2/COX-2 gene was significantly 
increased by LFH treatment. COX-1 and COX-2 are the first and rate-limiting 
enzymes involved in the conversion of arachidonic acid to prostaglandins, 
thromboxane A2 and prostacyclin. It is generally assumed that COX-2 plays a 
detrimental role in cardiovascular homeostasis since COX-2-derived 
thromboxanes might induce vasoconstriction and potentiate an inflammatory 
state. However, in healthy humans, COX-2 generates mainly prostacyclin, a 
potent vasodilator and platelet inhibitor (McAdam et al., 1999). Moreover, it has 
been described that ACE inhibitors increase expression of COX-2 and 
prostacyclin levels in different experimental models (Kohlstedt, Busse, & Fleming, 
2005) thus suggesting that COX-2 induction, like that provoked by LFH, may 
potentiate vasodilator activity. VPP and IPP treatment in SHR significantly 
increased the expression of COX-1 gene in aorta, but not that of COX-2 
(Yamaguchi, Kawaguchi, & Yamamoto, 2009). In this work, although a slight 
increase in the expression of COX-1 gene was detected (1.28-fold), it did not 
reach statistical significance (P = 0.0609). Involvement of COX in the 
antihypertensive effect of milk-derived peptides deserves further research. 
 ACE inhibitors are considered to act protectively on endothelium by 
inhibiting production of angiotensin II and degradation of bradykinin, which 
facilitates NO production. NO is an endogenous vasodilatory gaseous molecule 
that continuously regulates the diameter of blood vessels and maintains an anti-
proliferative and anti-apoptopic environment in the vessel wall, thus contributing 
to protect the endothelium (Sessa, 2004). The action of NO as a vasodilator is 
mediated by the activation of vascular smooth muscle soluble guanylate cyclase 
(sGC), the physiological receptor for NO (Arnold, Mittal, Katsuki, & Murad, 1977) 
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and presumably the most relevant molecular target for NO-releasing drugs in 
human cardiovascular therapy (Zabel, Weeger, La, & Schmidt, 1998). sGC is a 
signal transduction enzyme that forms the second messenger molecule cyclic 
GMP which in turn modulates the activity of several effector proteins that lead to 
vasorelaxation (Schmidt, Lohmann, & Walter, 1993). Our results showed 
increased NO production and upregulated expression of sGC (GUCY1) following 
LFH treatment in HUVEC, suggesting an elevation of cyclic GMP in HUVEC, as 
described for vasodilator compounds which in vivo activate sGC in vascular 
tissue (Galle et al., 1999). 
Endothelial NO is produced by eNOS which converts the amino acid L-
arginine into L-citrulline and NO (Geller & Billiar, 1998). eNOS is tightly controlled 
by co- and post-translational lipid modifications, phosphorylation on multiple 
residues and regulated protein-protein interactions (Qian & Fulton, 2013). 
Significant increases of eNOS at mRNA or protein levels in aorta of SHR after 
administration of VPP and IPP (Yamaguchi, Kawaguchi, & Yamamoto, 2009) or 
a casein hydrolysate (Sánchez et al., 2011) have been reported, as well as an 
increase in eNOS phosphorylation in endothelial cells cultured with ACE-
inhibitory peptides (Shimizu et al., 2010; Ko et al., 2012). In our study, LFH 
treatment showed no effect on eNOS mRNA (Table 2) or protein levels (results 
not shown). By contrast, data reported here reveal eNOS-interacting protein 
NOSTRIN as a target for LFH in endothelial cells. In HUVEC, NOSTRIN 
expression was significantly downregulated after LFH treatment for 24 h. 
Moreover, this result was consistent with the reduced protein expression detected 
by immunoblot analysis (60%) and the increased NO production (45%) observed 
in HUVEC after 24h LFH treatment. NOSTRIN is a protein which modulates 
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subcellular distribution of eNOS and thus NO release. Overexpression of 
NOSTRIN can promote the translocation of eNOS from the plasma membrane to 
intracellular vesicles, with a concomitant reduction in eNOS enzyme activity and 
inhibition of NO synthesis (Zimmermann et al., 2002). Conversely, decreased 
NOSTRIN expression also influences eNOS subcellular localization and 
contributes to increase NO levels in endothelial cells (McCormick et al., 2011). 
To the best of our knowledge this is the first time that NOSTRIN is pointed out as 
a target for antihypertensive peptides. 
Other enzymes involved in the NO pathway have been proposed as 
molecular targets for antihypertensive peptides. Treatment of endothelial cells 
with a snake venom antihypertensive peptide was related to the activation of 
argininosuccinate synthetase, a key enzyme of the arginine-citrulline cycle which 
provides arginine to eNOS (Guerreiro et al., 2009). In this context, our results 
show a modest but significant 30% increase in relative abundance of ARG2 
mRNA in LFH-treated HUVEC. ARG2 encodes for one of the two isoforms of 
mammalian arginase, the enzyme which shares and competes for the substrate 
L-arginine with eNOS in endothelial cells. Increased expression of arginase II 
encoded by ARG2 reduces basal NO synthesis (Li et al., 2001), and this has been 
proposed as a protective mechanism against the toxicity generated by NO 
overproduction and NO-derived radicals (Dawson, Dawson, London, Bredt, & 
Snyder, 1991; Gotoh & Mori, 1999). Further research is in progress to investigate 
the participation of eNOS and enzymes involved in arginine metabolism in the 
antihypertensive effect of LFH. 
In contrast to that found for LFH, the sequences LIWKL and RPYL did not 
elicit any significant change in the level of expression of PTGS2/COX-2, 
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GUCY1A3 or NOSTRIN genes. These results might reveal a negligible 
contribution of both peptides to the effects on mRNA levels provoked by LFH 
treatment, at least at the time point tested, and suggest that other peptides of the 
hydrolysate could contribute to such effect on gene expression in HUVEC. 
Synergistic effects of individual peptides cannot be discarded as suggested for 
the stimulatory effect on mucin gene expression in human intestinal cells of a 
casein hydrolysate and derived peptides (Martínez-Maqueda, Miralles, Cruz-
Huerta, & Recio, 2013). Finally, stability of LFH and peptides in HUVEC during 
treatment has not been addressed here, and potential degradation by the action 
of cellular peptidases including ACE should be considered. Undoubtedly the 
possible effects of individual sequences contained in LFH as well as 
bioavailability issues merit further research.  
5. Conclusions 
This in vitro study showed that LFH was able to inhibit ACE, modify the 
expression of hypertension-related genes and increase NO production in human 
endothelial cells. The HUVEC in vitro model used in this study is a widely 
validated model and has allowed us the detailed analysis of human gene 
expression, although data on the mechanism of action of LFH and derived 
peptides in human subjects need to be obtained. Work is underway to fulfill this 
issue. Data from the human in vitro model suggest NOSTRIN as a target for LFH. 
NOSTRIN downregulation at both mRNA and protein levels could be partly 
responsible for the enhanced NO production in HUVEC at the concentration 
tested. Other concentrations which would be closer to a physiological situation 
need to be tested in order to confirm the role of NOSTRIN as a functional target 
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of LFH. Results from the PCR array serve as a ground point for future studies on 
the complex mechanism of action underlying the antihypertensive effects of ACE-
inhibitory peptides derived from food proteins, including lactoferrin-derived 
peptides. 
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Figure captions 
Figure 1. Effect of LFH (700 µg/mL), LIWKL (100 µM) and RPYL (100 µM) on 
GUCY1A3 (A), NOSTRIN (B) and PTGS2 (C) mRNA level in cultured human 
endothelial cells determined by qRT-PCR. Data are mean ± SEM of three 
independent assays. *Significantly different from control P < 0.05 (Students t
test). 
Figure 2. NOSTRIN protein level in LFH-treated cultured human endothelial cells 
by Western-blot analysis. Data are mean ± SEM of three independent assays. 
*Significantly different from control P < 0.05 (Students t-test). A representative 
Western blot analysis is shown in the upper panel. 
Figure 3. Time-dependent induction of NO production, measured as nitrite, by 
LFH in cultured human endothelial cells. Black bar: untreated-HUVEC; white bar: 
LFH-treated HUVEC. Data are mean ± SEM of 6 independent assays. 
*significantly different from control P < 0.05 (Students t-test). 
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Table 1. Time-course of ACE inhibitory activity of LFHa in cultured human 
endothelial cells 
Time (h) ACE residual activity (%)b
1 15.3 ± 0.4** 
3 23.1 ± 0.1** 
6 28.5 ± 0.8** 
24 38.6 ± 0.4** 
aFinal concentration in the assay 700 µg/mL. 
bData are expressed as the percentage of ACE residual activity with respect to a 
non-treated control (100%) and are the mean  SEM of 3 independent 
experiments. **Significant inhibition with respect to control, P < 0.01 (Students t-
test on un-shown absolute values of ACE activity). 
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Table 2. Effect of LFHa on hypertension-related gene expression in cultured human endothelial cells. 
Gene Description Fold change 
ACE Angiotensin I converting enzyme (peptidyl-dipeptidase A) 1 -1.65 
ACTA2 Actin, alpha 2, smooth muscle, aorta -1.20 
ADM Adrenomedullin 1.58 
ADRA1D Adrenergic, alpha-1D-, receptor 1.64 
ADRB1 Adrenergic, beta-1-, receptor 1.05 
ARG2 Arginase, type II 1.30*
ATP2C1 ATPase, Ca++ transporting, type 2C, member 1 1.05 
ATP6AP2 ATPase, H+ transporting, lysosomal accessory protein 2 -1.35*
AVPR1B Arginine vasopressin receptor 1B 1.35 
BMPR2 Bone morphogenetic protein receptor, type II (serine/threonine kinase) -1.27 
CAV1 Caveolin 1, caveolae protein, 22kDa 1.04 
CHRNA1 Cholinergic receptor, nicotinic, alpha 1 (muscle) 1.08 
CHRNB1 Cholinergic receptor, nicotinic, beta 1 (muscle) 1.08 
CLIC1 Chloride intracellular channel 1 -1.33 
CLIC4 Chloride intracellular channel 4 -1.15 
CLIC5 Chloride intracellular channel 5 -2.70 
ECE1 Endothelin converting enzyme 1 -1.18 
EDN1 Endothelin 1 1.57 
EDN2 Endothelin 2 -2.56 
EDNRA Endothelin receptor type A -1.23 
EDNRB Endothelin receptor type B -1.00 
EPHX2 Epoxide hydrolase 2, cytoplasmic -1.52 
GCH1 GTP cyclohydrolase 1 -1.07 
GCHFR GTP cyclohydrolase I feedback regulator -1.43 
GUCY1A3 Guanylate cyclase 1, soluble, alpha 3 4.42**
33 
GUCY1B3 Guanylate cyclase 1, soluble, beta 3 1.81*
HIF1A Hypoxia inducible factor 1, alpha subunit (basic helix-loop-helix transcription factor) -1.13 
ITPR1 Inositol 1,4,5-trisphosphate receptor, type 1 -1.09 
ITPR2 Inositol 1,4,5-trisphosphate receptor, type 2 -1.10 
KCNMA1 Potassium large conductance calcium-activated channel, subfamily M, alpha member 1 -1.17 
MYLK Myosin light chain kinase 1.21 
MYLK2 Myosin light chain kinase 2 -1.19 
NOS3 Nitric oxide synthase 3 (endothelial cell) 1.17 
NOSIP Nitric oxide synthase interacting protein 1.20 
NOSTRIN Nitric oxide synthase trafficking -2.45**
NPR1 Natriuretic peptide receptor A/guanylate cyclase A (atrionatriuretic peptide receptor A) -1.56 
P2RX4 Purinergic receptor P2X, ligand-gated ion channel, 4 1.22 
PDE3A Phosphodiesterase 3A, cGMP-inhibited -1.20 
PDE3B Phosphodiesterase 3B, cGMP-inhibited -1.27 
PDE5A Phosphodiesterase 5A, cGMP-specific 1.11 
PLCG1 Phospholipase C, gamma 1 -1.31 
PLCG2 Phospholipase C, gamma 2 (phosphatidylinositol-specific) -1.13 
PRKG1 Protein kinase, cGMP-dependent, type I 1.03 
PTGIR Prostaglandin I2 (prostacyclin) receptor (IP) 1.22 
PTGS1 Prostaglandin-endoperoxide synthase 1 (prostaglandin G/H synthase and cyclooxygenase) 1.28 
PTGS2 Prostaglandin-endoperoxide synthase 2 (prostaglandin G/H synthase and cyclooxygenase) 2.23*
S1PR1 Sphingosine-1-phosphate receptor 1 -1.19 
SCNN1A Sodium channel, nonvoltage-gated 1 alpha -1.79 
SLC7A1 Solute carrier family 7 (cationic amino acid transporter, y+ system), member 1 1.04 
SPHK1 Sphingosine kinase 1 -1.39 
SPHK2 Sphingosine kinase 2 -1.03 
aFinal concentration in the assay 700 µg/mL. 
bFold change was calculated by the CT method . *significantly different from control P < 0.05; ** significantly different from control 
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